Clinical trial
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
NCT06497530
Study timeline
Study start (actual)2024-12-01Date precision: day
Registry last updated2026-06-08
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Extensive-Stage Small Cell Lung Cancerunresolved
Interventions
SerplulimabDRUG
LurbinectedinDRUG · verified · RxNorm: lurbinectedin
CarboplatinDRUG · verified · RxNorm: carboplatin
EtoposideDRUG · verified · RxNorm: etoposide
Sponsors & collaborators
Guangzhou Institute of Respiratory Diseaselead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06497530 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.